The association of dabrafenib with an anti-MEK therapy i. e. trametinib, also showed a significantly higher overall survival than vemurafenib alone in BRAF mutated patients with metastatic melanoma [4]. The gene discussed is MAP2K7; the disease is metastatic melanoma.